TENKU Citius Oncology Inc. - Units (1 Ord & 1 Rts)

About TENKU

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
50

Neutral Sentiment

How do you feel about TENKU?

Advertisement|Remove ads.